ID   K6H6/B5
AC   CVCL_2538
SY   K6H6-B5; K6H6B5
DR   BTO; BTO:0002208
DR   CLO; CLO_0007064
DR   CLDB; cl2994
DR   AddexBio; C0033002/4944
DR   ATCC; CRL-1823
DR   ECACC; 89101606
DR   Wikidata; Q54899426
RX   PubMed=1651789;
RX   PubMed=3084658;
RX   PubMed=7492749;
CC   Group: Hybridoma fusion partner cell line.
CC   Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_2155 ! P3/NS1/1-Ag4.1
CA   Hybrid cell line
DT   Created: 04-04-12; Last updated: 21-03-23; Version: 13
//
RX   PubMed=1651789; DOI=10.3233/HAB-1991-2306;
RA   Perkins S., Zimmermann U., Foung S.K.H.;
RT   "Parameters to enhance human hybridoma formation with hypoosmolar
RT   electrofusion.";
RL   Hum. Antibodies Hybridomas 2:155-159(1991).
//
RX   PubMed=3084658; DOI=10.1016/0022-1759(86)90032-3;
RA   Carroll W.L., Thielemans K., Dilley J., Levy R.;
RT   "Mouse x human heterohybridomas as fusion partners with human B cell
RT   tumors.";
RL   J. Immunol. Methods 89:61-72(1986).
//
RX   PubMed=7492749; DOI=10.3233/HAB-1995-6201;
RA   Delvig A.A., Koumare B., Glaser R.W., Wang J.-F., Jahn S., Achtman M.;
RT   "Comparison of three human-murine heteromyeloma cell lines for
RT   formation of human hybridomas after electrofusion with human
RT   peripheral blood lymphocytes from meningococcal cases and carriers.";
RL   Hum. Antibodies Hybridomas 6:42-46(1995).
//